What’s Up With mRNA Research? A research nurse holds an injection of a BioNTech mRNA cancer immunotherapy for non-small cell ...

Scientists say that officials from the National Institutes of Health urged them to remove references to mRNA vaccine ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

The European Patent Office declared a patent owned by CureVac , valid, after a challenge from drugmaker BioNTech , the company said on Thursday.

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $25.0 to $70.0 for Moderna over the recent three months. In terms of liquidity ...

Customers looking for an mRNA therapeutic partner should prioritize operational excellence and choose flexible CDMOs.

A handful of states are targeting the technology at the same time the Trump administration is cutting research funding and ...

The vaccine — using messenger RNA (mRNA) technology similar to that found in some Covid vaccines — activated tumour-targeting immune cells that persisted for nearly four years after surgery in ...

Before joining Moderna, Cronin spent close to 20 years at Ogilvy, working within its global healthcare department in ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

The fears over mRNA-vaccine grant cancellations come after NIH staff members were instructed to compile a list of grants for ...

Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. The stock rose 7% to $2.99 on Friday. Shares ...